Loading...
XNASVRNA
Market cap472mUSD
Dec 27, Last price  
46.19USD
1D
-1.13%
1Q
60.61%
Jan 2017
92,280.00%
IPO
65,885.71%
Name

Verona Pharma PLC

Chart & Performance

D1W1MN
XNAS:VRNA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-9.61%
Rev. gr., 5y
-24.29%
Revenues
0k
-100.00%
0000000000001,841,0002,7832,351040,000,000458,0000
Net income
-54m
L-20.86%
44,73800000000000000-65,146,000-55,569,000-68,701,000-54,369,000
CFO
-50m
L-16.10%
000000000000000-45,076,000-33,254,000-59,862,000-50,222,000
Earnings
Apr 25, 2025

Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
URL
https://www.veronapharma.com/
IPO date
Mar 30, 2005
Employees
35
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
458
-98.86%
40,000
 
Cost of revenue
17,962
76,208
113,313
Unusual Expense (Income)
NOPBT
(17,962)
(75,750)
(73,313)
NOPBT Margin
Operating Taxes
(632)
253
(18)
Tax Rate
NOPAT
(17,330)
(76,003)
(73,295)
Net income
(54,369)
-20.86%
(68,701)
23.63%
(55,569)
-14.70%
Dividends
Dividend yield
Proceeds from repurchase of equity
56,909
145,890
(4,332)
BB yield
Debt
Debt current
1,180
675
648
Long-term debt
53,104
10,853
6,094
Deferred revenue
Other long-term liabilities
Net debt
(232,488)
(231,299)
(156,638)
Cash flow
Cash from operating activities
(50,222)
(59,862)
(33,254)
CAPEX
(29)
(12)
Cash from investing activities
(29)
(12)
Cash from financing activities
92,869
140,818
(6,117)
FCF
(29,698)
(75,951)
(72,004)
Balance
Cash
271,772
227,827
148,380
Long term investments
15,000
15,000
15,000
Excess cash
286,772
242,804
161,380
Stockholders' equity
(350,263)
(297,172)
(236,462)
Invested Capital
650,875
538,003
390,128
ROIC
ROCE
EV
Common stock shares outstanding
79,268
66,134
59,149
Price
Market cap
EV
EBITDA
(17,846)
(75,114)
(72,684)
EV/EBITDA
Interest
2,065
521
340
Interest/NOPBT